Inhaled Nitric Oxide Market Size, Share & Industry Analysis, By Application (Neonatal Respiratory Treatment, COPD (Chronic Obstructive Pulmonary Disease), Malaria Treatment, Tuberculosis Treatment, ARDS (Acute Respiratory Distress Syndrome), Chronic Wound Healing, Others) And Regional Forecast, 2024-2032

Inhaled nitric oxide (iNO) is soluble in water and appears as a colorless and odourless gas. It is a pulmonary vasodilator that plays a major role in guanylyl cyclase activation, which leads to the manufacturing of subsequent smooth muscle relaxation and cyclic guanosine monophosphate. Moreover, inhaled nitric oxide offers therapeutic benefits, and used for the treatment of several respiratory associated diseases. The product is also ideal for treating some premature patients suffering from acute respiratory distress syndrome or lung disease of prematurity. Inhaled nitric oxide finds its application in neonatal respiratory treatment, COPD (chronic obstructive pulmonary disease), malaria treatment, and tuberculosis treatment. 

The inhaled nitric oxide market is growing at a rapid pace owing to increasing its demand from various industries. For neonatal respiratory treatment, the product is used together with a breathing machine or ventilator to treat respiratory failure in premature babies. Also, the product aids in relaxing the smooth muscle that can widen dilate blood vessels, especially in the lungs. The rapidly growing healthcare industry, increase in the prevalence of respiratory diseases such as chronic obstructive pulmonary disease and asthma, and rising geriatric population with a progressive weakening in lung function may upsurge the consumption of inhaled nitric oxide. Hence, this will fuel market growth during the forecast period.   

However, strict applicable norms by the governments in various region over the product use is restraining the inhaled nitric oxide market growth during the review period.

Market Segmentation:

Based on application, the inhaled nitric oxide market is segmented into neonatal respiratory treatment, COPD (chronic obstructive pulmonary disease), malaria treatment, tuberculosis treatment, ARDS (acute respiratory distress syndrome), chronic wound healing, and others. From a geographical standpoint, the market is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.  

Key Players Covered:

The key players in the inhaled nitric oxide market include Nu-Med Plus, Inc., Genosys Inc., Praxair, Inc., Air Liquide S.A., Mallinckrodt Pharmaceuticals, Linde plc., Sigma-Aldrich Co., Novoteris, Ikaria Canada Inc., Geno, Perma Pure, and Praxair Technology, Inc.

Key Insights

• Key Emerging Trends – For Major Countries


• Key Developments: Mergers, Acquisition, Partnership, etc.


• Latest Technological Advancement


• Insights on Regulatory Scenarios


• Porters Five Forces Analysis

Regional Analysis:

North America is anticipated to witness sustainable growth in the inhaled nitric oxide market. The growth is attributed to the rising product demand in neonatal respiratory treatment. The rapid growth in the healthcare industry will fuel the inhaled nitric oxide market growth in Europe, in which UK and Germany are the leading countries. In Asia Pacific, the growth is due to the increasing use of the product in malaria treatment and chronic wound healing. The Middle East & Africa is anticipated to witness significant growth, owing to the rising product adoption in the ARDS and tuberculosis treatment.

Segmentation